John Overdeck’s Guardant Health GH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.34M Buy
+8,900
New +$968K ﹤0.01% 3380
2026
Q1
Sell
-2,000
Closed -$204K 4713
2025
Q4
$204K Buy
+2,000
New +$179K ﹤0.01% 3755
2021
Q4
Sell
-7,100
Closed -$888K 4491
2021
Q3
$888K Buy
7,100
+4,100
+137% +$487K ﹤0.01% 2712
2021
Q2
$373K Buy
+3,000
New +$404K ﹤0.01% 3334
2020
Q2
Sell
-9,800
Closed -$682K 3154
2020
Q1
$682K Buy
9,800
+5,700
+139% +$437K 0.01% 1711
2019
Q4
$320K Sell
4,100
-1,700
-29% -$123K ﹤0.01% 3140
2019
Q3
$370K Buy
+5,800
New +$511K ﹤0.01% 2791

Other funds holding GH

John Overdeck's GH Position: Q2 2026 in Review

John Overdeck reduced its Guardant Health (GH) stake by 12% in Q2 2026, selling an estimated $55.5M and leaving 3,719,301 shares worth $558M. The position accounts for 0.4% of the portfolio, ranked #39.

John Overdeck first reported a position in GH in Q3 2019 and has held it in 22 quarters since. 595 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • John Overdeck held 3,719,301 shares of Guardant Health worth $558M as of Q2 2026.
  • John Overdeck sold 510,230 Guardant Health shares in Q2 2026, an estimated $55.5M.
  • Guardant Health made up 0.4% of John Overdeck's portfolio in Q2 2026, its #39 holding.
  • John Overdeck first reported a position in Guardant Health in Q3 2019 and has held it in 22 quarters since.
  • 595 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.